EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study

Sasivimon Ratree, Nicha Assavapokee iD, Somsook Santibenchakul, Nakarin Sirisabya, Waranyoo Phoolcharoen, Natacha Phoolcharoen iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0342303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Sasivimon Ratree und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, COVID-19 Vaccines, COVID-19, Vaccination. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Data on the safety of coronavirus disease 19 (COVID-19) vaccines in gynecologic cancer patients are scarce. The type of vaccine used in Thailand differs from what has been studied in other countries. This study evaluated the prevalence and characteristics of reported adverse events following COVID-19 vaccines in patients with gynecologic cancer patients.

Method

A retrospective, single-center descriptive study was performed in patients with gynecologic cancer who received at least one dose of the COVID-19 vaccine at King Chulalongkorn Memorial Hospital, Thailand, from January 2020 to August 2021. Adverse events were collected through structured telephone interviews using a standardized questionnaire. Descriptive statistics summarized patient characteristics and adverse events. Associations with any-grade adverse events were assessed using logistic regression and Fisher’s exact test for categorical variables.

Results

Of the 294 patients interviewed, 72.8% were in remission, under surveillance, or in palliative treatment at the time of vaccination, and 17.7% were undergoing treatment. The most common adverse effects were grade 1–2 injection site reactions. One patient developed grade 3 fever and seizures 10 days after the first dose of the AstraZeneca vaccine. Between the second and fourth doses of the vaccination, the most common adverse events were grade 1–2 injection site reactions. No severe allergic reactions or grade 4 adverse events were reported. The study concluded that patients under 60 years of age had more adverse events than older patients (adjusted odds ratio 1.99, 95% confidence interval 1.08–3.71 p = 0.029). The treatment status did not affect adverse events. Of 283 patients who received two doses, 27.6% were infected with COVID-19.

Conclusion

COVID-19 vaccination was generally well tolerated among gynecological cancer patients who received active anticancer therapy and those under surveillance. Younger patients frequently reported more adverse effects than older patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleCOVID-19 VaccinesCOVID-19VaccinationHumansFemaleThailandMiddle AgedRetrospective StudiesAgedAdultSARS-CoV-2Aged, 80 and overInjection Site Reaction

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Center of Excellence in Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.
  • Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Nicha Assavapokee, Natacha Phoolcharoen

Zitieren

APA

Ratree, S., Assavapokee, N., Santibenchakul, S., Sirisabya, N., Phoolcharoen, W., & Phoolcharoen, N. (2026). Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study. PLOS One. https://doi.org/10.1371/journal.pone.0342303

Vancouver

Ratree S, Assavapokee N, Santibenchakul S, Sirisabya N, Phoolcharoen W, Phoolcharoen N. Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study. PLOS One. 2026. doi:10.1371/journal.pone.0342303

BibTeX
@article{Ratree2026,
  author = {Ratree, Sasivimon and Assavapokee, Nicha and Santibenchakul, Somsook and Sirisabya, Nakarin and Phoolcharoen, Waranyoo and Phoolcharoen, Natacha},
  title = {Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0342303}
}
Kostenlos starten →